Novavax vaccine shows 51% efficacy against SA variant of Covid-19


Novavax Inc's Covid-19 vaccine had efficacy of 51% against infections caused by the SA variant among people who were HIV negative, and 43% in a group that included people who were HIV positive, according to a new analysis. These findings were  published in the New England Journal of Medicine, reported Reuters (6 May 2021).The Novavax post-hoc analysis included nearly 2,700 volunteers who had not been previously infected with the coronavirus. Results announced in January showed efficacy of 60.1% against symptomatic Covid-19 in the SA trial looking at a mixture of the original virus and the SA variant among those who were HIV-negative. Efficacy was 49.4% among a mixed group of HIV positive and HIV negative participants.

Other news